Systemic delivery of tyrosine-mutant AAV vectors results in robust transduction of neurons in adult mice

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Iida, Asako ^a   Takino, Naomi ^a   Miyauchi, Hitomi ^a   Shimazaki, Kuniko ^a   Muramatsu, Shin Ichi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; MICRORNA; TYROSINE;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; MALE; MOUSE; MUTANT; NONHUMAN; SPINAL CORD; VIRAL GENE DELIVERY SYSTEM; AGING; ANIMAL; BRAIN; C57BL MOUSE; CYTOLOGY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; GLIA; METABOLISM; MOTONEURON; MUTATION; NERVE CELL; PROMOTER REGION; PURKINJE CELL; SUBSTANTIA NIGRA; DEPENDOPARVOVIRUS;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MUS;

AGING; ANIMALS; BRAIN; DEPENDOVIRUS; GENETIC VECTORS; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; MOTOR NEURONS; MUTATION; NEUROGLIA; NEURONS; PROMOTER REGIONS, GENETIC; PURKINJE CELLS; SPINAL CORD; SUBSTANTIA NIGRA; TRANSDUCTION, GENETIC; TYROSINE;

EID: 84878689856     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/974819     Document Type: Article

References (43)

1. Bowers W. J., Breakefield X. O., Sena-Esteves M., Genetic therapy for the nervous system. Human Molecular Genetics 2011 20 R1 R28 R41 2-s2.0-79956056971 10.1093/hmg/ddr110
2. High K. A., Aubourg P., rAAV human trial experience. Methods in Molecular Biology 2011 807 429 457
3. Weinberg M. S., Samulski R. J., McCown T. J., Adeno-associated virus (AAV) gene therapy for neurological disease. Neuropharmacology 2013 69 82- 88 10.1016/j.neuropharm.2012.03.004
4. Hadaczek P., Eberling J. L., Pivirotto P., Bringas J., Forsayeth J., Bankiewicz K. S., Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Molecular Therapy 2010 18 8 1458 1461 2-s2.0-77955175906 10.1038/mt.2010.106
5. Muramatsu S., Fujimoto K., Kato S., Mizukami H., Asari S., Ikeguchi K., Kawakami T., Urabe M., Kume A., Sato T., Watanabe E., Ozawa K., Nakano I., A phase I study of aromatic L-amino acid decarboxylase gene therapy for parkinson's disease. Molecular Therapy 2010 18 9 1731 1735 2-s2.0-77956262279 10.1038/mt.2010.135
6. Bartus R. T., Baumann T. L., Brown L., Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating, "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease. Neurobiology of Aging 2012 34 1 35 61
7. Christine C. W., Starr P. A., Larson P. S., Eberling J. L., Jagust W. J., Hawkins R. A., Vanbrocklin H. F., Wright J. F., Bankiewicz K. S., Aminoff M. J., Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009 73 20 1662 1669 2-s2.0-73449128979 10.1212/WNL. 0b013e3181c29356
8. LeWitt P. A., Rezai A. R., Leehey M. A., Ojemann S. G., Flaherty A. W., Eskandar E. N., Kostyk S. K., Thomas K., Sarkar A., Siddiqui M. S., Tatter S. B., Schwalb J. M., Poston K. L., Henderson J. M., Kurlan R. M., Richard I. H., Van Meter L., Sapan C. V., During M. J., Kaplitt M. G., Feigin A., AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. The Lancet Neurology 2011 10 4 309 319 2-s2.0-79952740079 10.1016/S1474-4422(11)70039-4
9. Bevan A. K., Duque S., Foust K. D., Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Molecular Therapy 2011 19 11 1971 1980 10.1038/mt.2011.157
10. Duque S., Joussemet B., Riviere C., Marais T., Dubreil L., Douar A. M., Fyfe J., Moullier P., Colle M. A., Barkats M., Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Molecular Therapy 2009 17 7 1187 1196 2-s2.0-67649861393 10.1038/mt.2009.71
11. Federici T., Taub J. S., Baum G. R., Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Therapy 2012 19 8 852 859 10.1038/gt.2011.130
12. Foust K. D., Nurre E., Montgomery C. L., Hernandez A., Chan C. M., Kaspar B. K., Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nature Biotechnology 2009 27 1 59 65 2-s2.0-60149106907 10.1038/nbt.1515
13. Rahim A. A., Wong A. M., Hoefer K., Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system. The FASEB Journal 2011 25 10 3505 3518 10.1096/fj.11-182311
14. Samaranch L., Salegio E. A., San Sebastian W., Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Human Gene Therapy 2012 23 4 382 389 10.1089/hum.2011.200
15. Glascock J. J., Osman E. Y., Wetz M. J., Decreasing disease severity in symptomatic, Smn(-/-);SMN2(+/+), spinal muscular atrophy mice following scAAV9-SMN delivery. Human Gene Therapy 2012 23 3 330 335 10.1089/hum.2011.166
16. Foust K. D., Wang X., McGovern V. L., Braun L., Bevan A. K., Haidet A. M., Le T. T., Morales P. R., Rich M. M., Burghes A. H. M., Kaspar B. K., Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nature Biotechnology 2010 28 3 271 274 2-s2.0-77749249680 10.1038/nbt.1610
17. McCarty D. M., Self-complementary AAV vectors; advances and applications. Molecular Therapy 2008 16 10 1648 1656 2-s2.0-54849162100 10.1038/mt.2008.171
18. Gray S. J., Matagne V., Bachaboina L., Yadav S., Ojeda S. R., Samulski R. J., Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Molecular Therapy 2011 19 6 1058 1069 2-s2.0-79957888016 10.1038/mt.2011.72
19. Ciesielska A., Hadaczek P., Mittermeyer G., Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Molecular Therapy 2012 21 1 158 166
20. Delzor A., Dufour N., Petit F., Restricted transgene expression in the brain with cell-type specific neuronal promoters. Human Gene Therapy Methods 2012 23 4 242 254
21. Ku C. A., Chiodo V. A., Boye S. L., Gene therapy using self-complementary Y733F capsid mutant AAV2/8 restores vision in a model of early onset Leber congenital amaurosis. Human Molecular Genetics 2011 20 23 4569 4581 10.1093/hmg/ddr391
22. Li M., Jayandharan G. R., Li B., Ling C., Ma W., Srivastava A., Zhong L., High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. Human Gene Therapy 2010 21 11 1527 1543 2-s2.0-78649375117 10.1089/hum.2010.005
23. Petrs-Silva H., Dinculescu A., Li Q., Deng W. T., Pang J. J., Min S. H., Chiodo V., Neeley A. W., Govindasamy L., Bennett A., Agbandje-Mckenna M., Zhong L., Li B., Jayandharan G. R., Srivastava A., Lewin A. S., Hauswirth W. W., Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Molecular Therapy 2011 19 2 293 301 2-s2.0-79551634862 10.1038/mt.2010.234
24. Qiao C., Zhang W., Yuan Z., Shin J. H., Li J., Jayandharan G. R., Zhong L., Srivastava A., Xiao X., Duan D., Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. Human Gene Therapy 2010 21 10 1343 1348 2-s2.0-77958102381 10.1089/hum.2010.003
25. Cheng B., Ling C., Dai Y., Lu Y., Glushakova L. G., Gee S. W. Y., McGoogan K. E., Aslanidi G. V., Park M., Stacpoole P. W., Siemann D., Liu C., Srivastava A., Ling C., Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. Gene Therapy 2012 19 4 375 384 2-s2.0-79960456701 10.1038/gt.2011.105
26. Dalkara D., Byrne L. C., Lee T., Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9. Gene Therapy 2012 19 2 176 181 10.1038/gt.2011.163
27. Zhang Y., Duan D., Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma. Human Gene Therapy 2012 23 1 98 103 10.1089/hum.2011.131
28. Dittgen T., Nimmerjahn A., Komai S., Licznerski P., Waters J., Margrie T. W., Helmchen F., Denk W., Brecht M., Osten P., Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo. Proceedings of the National Academy of Sciences of the United States of America 2004 101 52 18206 18211 2-s2.0-19944429120 10.1073/pnas.0407976101 (Pubitemid 40054098)
29. Meyuhas O., Klein A., The mouse ribosomal protein L7 gene. Its primary structure and functional analysis of the promoter region. Journal of Biological Chemistry 1990 265 20 11465 11473 2-s2.0-0025368830
30. Gao G., Vandenberghe L. H., Alvira M. R., Lu Y., Calcedo R., Zhou X., Wilson J. M., Clades of adeno-associated viruses are widely disseminated in human tissues. Journal of Virology 2004 78 12 6381 6388 2-s2.0-2642512201 10.1128/JVI.78.12.6381-6388.2004 (Pubitemid 38715936)
31. Li X. G., Okada T., Kodera M., Nara Y., Takino N., Muramatsu C., Ikeguchi K., Urano F., Ichinose H., Metzger D., Chambon P., Nakano I., Ozawa K., Muramatsu S. I., Viral-mediated temporally controlled dopamine production in a rat model of Parkinson disease. Molecular Therapy 2006 13 1 160 166 2-s2.0-28844437489 10.1016/j.ymthe.2005.08.009 (Pubitemid 41763494)
32. Wagner W., McCroskery S., Hammer J. A. III, An efficient method for the long-term and specific expression of exogenous cDNAs in cultured Purkinje neurons. Journal of Neuroscience Methods 2011 200 2 95 105
33. Nakai H., Fuess S., Storm T. A., Muramatsu S. I., Nara Y., Kay M. A., Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. Journal of Virology 2005 79 1 214 224 2-s2.0-10644289281 10.1128/JVI.79.1.214-224.2005 (Pubitemid 39650967)
34. Wang Y., Ling C., Song L., Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitation. Human Gene Therapy Methods 2012 23 4 225 233
35. Zhang H., Yang B., Mu X., Ahmed S. S., Su Q., He R., Wang H., Mueller C., Sena-Esteves M., Brown R., Xu Z., Gao G., Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Molecular Therapy 2011 19 8 1440 1448 2-s2.0-79961032418 10.1038/mt.2011.98
36. Philips T., Robberecht W., Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. The Lancet Neurology 2011 10 3 253 263 2-s2.0-79951704433 10.1016/S1474-4422(11)70015-1
37. Rappold P. M., Tieu K., Astrocytes and therapeutics for Parkinson's disease. Neurotherapeutics 2010 7 4 413 423 2-s2.0-77957048035 10.1016/j.nurt.2010.07.001
38. Horowitz E. D., Finn M. G., Asokan A., Tyrosine cross-linking reveals interfacial dynamics in adeno-associated viral capsids during infection. ACS Chemical Biology 2012 7 6 1059 1066 10.1021/cb3000265
39. Zhong L., Li B., Mah C. S., Govindasamy L., Agbandje-McKenna M., Cooper M., Herzog R. W., Zolotukhin I., Warrington K. H., Weigel-Van Aken K. A., Hobbs J. A., Zolotukhin S., Muzyczka N., Srivastava A., Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proceedings of the National Academy of Sciences of the United States of America 2008 105 22 7827 7832 2-s2.0-45549090635 10.1073/pnas.0802866105 (Pubitemid 351872723)
40. Petrs-Silva H., Dinculescu A., Li Q., Min S. H., Chiodo V., Pang J. J., Zhong L., Zolotukhin S., Srivastava A., Lewin A. S., Hauswirth W. W., High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Molecular Therapy 2009 17 3 463 471 2-s2.0-61649095399 10.1038/mt.2008.269
41. Miyazaki Y., Adachi H., Katsuno M., Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nature Medicine 2012 18 7 1136 1141 10.1038/nm.2791
42. Markusic D. M., Herzog R. W., Aslanidi G. V., Hoffman B. E., Li B., Li M., Jayandharan G. R., Ling C., Zolotukhin I., Ma W., Zolotukhin S., Srivastava A., Zhong L., High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Molecular Therapy 2010 18 12 2048 2056 2-s2.0-78650898983 10.1038/mt.2010.172
43. Naumer M., Sonntag F., Schmidt K., Properties of the adeno-associated virus assembly activating protein. Journal of Virology 2012 86 23 13038 13048 10.1128/JVI.01675-12